Form 4: Verona Pharma GC Cashes Out Equity in Merger

Verona Pharma's General Counsel, Andrew Fisher, reported significant equity transactions following the company's acquisition via a Scheme of Arrangement.

Summary

• Andrew Fisher, General Counsel of Verona Pharma plc, reported changes in beneficial ownership of the company's securities on October 7, 2025.
• The transactions are a direct result of a Scheme of Arrangement under Part 26 of the UK Companies Act 2006, stemming from a transaction agreement dated July 8, 2025.
• Verona Pharma plc was acquired by Merck Sharp & Dohme LLC and its wholly-owned subsidiary, Vol Holdings LLC.
• Under the Scheme of Arrangement, holders of Scheme Shares received $13.375 in cash per Ordinary Share.
• Holders of American Depositary Shares (ADSs), each representing eight Ordinary Shares, received $107 in cash per ADS.
• All outstanding time-based Restricted Share Unit (RSU) awards and performance-based Restricted Share Unit (PRSU) awards became fully vested immediately prior to the Effective Time of the Scheme.
• These vested RSU and PRSU awards were automatically converted into a cash amount equal to the product of the underlying ADSs and the $107 ADS Consideration.
• Outstanding share options also became fully vested, and those with an exercise price less than the ADS Consideration were converted into cash based on the difference between the ADS Consideration and the exercise price.
• Andrew Fisher disposed of 417,903 Ordinary Shares and 931,984 Ordinary Shares as part of the Scheme of Arrangement.
• He also acquired 931,984 Ordinary Shares through the vesting of equity awards and subsequently disposed of them as part of the Scheme.
• Derivative securities, including RSUs (equivalent to 146,168 and 167,056 Ordinary Shares) and PRSUs (equivalent to 618,760 Ordinary Shares), were converted to cash.
• Share options to buy 2,240,000 Ordinary Shares at an exercise price of $2.0113 were also converted to cash.

Sentiment

Score: 7

Explanation: The sentiment is positive as the filing details the successful completion of an acquisition, resulting in a cash payout for shareholders and the executive's equity. While the company ceases to exist independently, the transaction itself is a positive outcome for the selling shareholders.

Positives

• Shareholders, including the reporting person, received a cash payout for their equity holdings, indicating a successful exit for investors at the agreed acquisition price.
• Equity awards (RSUs, PRSUs, and in-the-money share options) held by the General Counsel were fully vested and converted to cash, providing liquidity and value realization for the executive.

Negatives

• Verona Pharma plc will no longer operate as an independent publicly traded entity, removing its stock from the market.
• The executive's equity holdings are fully cashed out, meaning no future upside potential from Verona Pharma's stock performance as an independent company.

Future Outlook

The filing reports the completion of an acquisition, indicating that Verona Pharma plc will no longer operate as an independent entity. No forward-looking statements regarding the company's future operations are provided.

Management Comments

• "Reported securities are represented by American Depositary Shares ('ADSs'), each of which represents eight (8) Ordinary Shares of the Issuer."
• "At the effective time of the Scheme of Arrangement (the 'Effective Time'), each holder of the Scheme Shares... became entitled to receive $13.375 in cash per Scheme Share..."
• "Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award... became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash..."
• "These performance-based restricted share unit awards (the 'PRSUs') were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved."
• "Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash..."

Industry Context

This transaction reflects a common trend in the pharmaceutical and biotechnology industry where smaller, specialized companies like Verona Pharma are acquired by larger pharmaceutical giants such as Merck Sharp & Dohme. Such acquisitions often aim to integrate promising drug candidates or technologies into a broader portfolio, providing an exit for early investors and a strategic asset for the acquirer.

Comparison to Industry Standards

• The cash-out mechanism for outstanding equity awards (RSUs, PRSUs, and in-the-money options) is a standard practice in M&A transactions, ensuring that employees and executives are compensated for their vested and earned equity upon a change of control.
• The premium paid per share/ADS in an acquisition is typically evaluated against the target company's pre-announcement trading price and comparable transactions in the biotech/pharma sector. While specific comparable companies are not mentioned, the cash consideration of $13.375 per Ordinary Share and $107 per ADS represents the agreed-upon valuation for the company in this acquisition.

Related Party Transactions

• The transaction involves Verona Pharma plc, Merck Sharp & Dohme LLC (Parent), and Vol Holdings LLC (Bidco), where Bidco is a wholly-owned subsidiary of Parent, indicating a related-party acquisition structure.

Stakeholder Impact

• Shareholders: Received $13.375 per Ordinary Share or $107 per ADS in cash, realizing value from their investment.
• Employees (specifically General Counsel): Equity awards were fully vested and converted to cash, providing a significant financial payout.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Transaction, Acquisition, Merger, Scheme of Arrangement, Merck Sharp & Dohme, Equity Compensation, Restricted Share Units, Share Options